Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Barclays PLC

Barclays PLC boosted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 295.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,217 shares of the company's stock after buying an additional 42,012 shares during the period. Barclays PLC owned 0.12% of Enliven Therapeutics worth $1,435,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Turn Management LLC lifted its stake in shares of Enliven Therapeutics by 29.5% during the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company's stock worth $13,666,000 after purchasing an additional 121,849 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company's stock valued at $19,164,000 after buying an additional 67,813 shares during the last quarter. Ally Bridge Group NY LLC purchased a new stake in shares of Enliven Therapeutics during the third quarter valued at about $5,998,000. Patient Square Capital LP bought a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at about $2,313,000. Finally, Bank of New York Mellon Corp grew its position in shares of Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company's stock worth $2,667,000 after buying an additional 37,632 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

Insider Transactions at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,270 shares of the company's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $27.67, for a total value of $35,140.90. Following the sale, the director now directly owns 124,490 shares of the company's stock, valued at $3,444,638.30. This represents a 1.01 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Anish Patel sold 21,700 shares of the firm's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,838 shares of company stock worth $1,112,061. Company insiders own 29.20% of the company's stock.

Enliven Therapeutics Trading Down 10.0 %

NASDAQ:ELVN opened at $21.74 on Monday. Enliven Therapeutics, Inc. has a twelve month low of $10.90 and a twelve month high of $30.03. The company has a market cap of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04. The company's 50 day moving average is $24.54 and its two-hundred day moving average is $24.43.

Analyst Ratings Changes

A number of equities research analysts recently commented on ELVN shares. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a "buy" rating and a $42.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Finally, Robert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Enliven Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $38.25.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.